A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Clinical trial NCT06630806 · RECRUITING

Trial details

NCT number: NCT06630806
Sponsor: Sanofi
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Plasma Cell Myeloma Refractory

Start date: 2024-10-30
Primary completion: 2031-05-16
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.